SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in south Indian coronary artery disease patients: supplementary files

dataset

posted on 2022-08-15, 09:38 authored by Govindaswamy Bharath, Durairaj Pandian Vishnuprabu, Loganathan Preethi, Arumugam Suriyam Nagappan, Ramia Thiagaraja Dhianeshwaran Isravanya, Lakkakula VKS Bhaskar, Nagarajan Swaminathan, Arasambattu Kannan Munirajan

Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the

drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved

in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods:

Genotyping was performed using 5?-hydrolysis probe method (n = 412), and the study evaluated the

treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density

lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642

genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing

the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction.

Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin,

and this may be useful in genotype-guided statin therapy for coronary artery disease patients.

Funding

This project was supported by the Indian Council of Medical Research (ICMR) Extramural research grant (no. 82/15/2012/PHGEN[TF]/BMS). We also acknowledge the department’s infrastructural support provided by UGC-SAP and DSTFIST from the Government of India.

History

Usage metrics

Keywords

atorvastatin ATP binding cassette transporters cytochrome P450 drug efficacy pharmacogenomics solute carrier transporters

Licence

CC BY-NC-ND 4.0